GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2010

VentiRx Pockets $25M to Fund Clinical Development of TLR8 Candidates

  • VentiRx Pharmaceuticals raised $25 million in a Series A Extension financing round. The new investment will be used to fund continued clinical development of VentiRx’ toll-like receptor 8 (TLR8) candidates for the treatment of cancer as well as respiratory and inflammatory diseases.

    VentiRx’ lead candidates are VTX-1462 for the treatment of allergic rhinitis and VTX-2337 for oncology indications; both are in Phase I development. VTX-1462 is a small molecule TLR8 agonist administered intranasally. VentiRx claims the molecule is the first selective TLR8 compound to reach the clinic for allergy. VTX-2337 is a small molecule TLR8 agonist designed to stimulate myeloid dendritic cells and monocytes and enhance NK-cell responses. It is administered subcutaneously on a weekly basis.

    VentiRx is also developing small molecule antagonists that inhibit responses to TLR8. The firm’s lead preclinical candidate, VTX-763, has demonstrated inhibition of TNFα production in vitro and inhibits TLR8-induced NF-kB activation.

    The new financing was led by MedImmune Ventures, the venture capital fund of AstraZeneca’s MedImmune biologics business. Existing investors including ARCH Venture Partners, Domain Associates, and Frazier Healthcare Ventures also participated. To date VentiRx has raised $56.1 million in Series A investments.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »